Trial · NCT07909668
Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
NCT07909668, Not applicable, Enrolling by invitation, Kafrelsheikh University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo. Trials, record NCT07909668. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909668
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
- NCT number
- NCT07909668
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Kafrelsheikh University
- Conditions
- Vitiligo, Nonsegmental Vitiligo
- Interventions
- Tacrolimus 0.1% ointment, Ruxolitinib 1.5% cream, 308-nm excimer laser
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Degree of repigmentation by Physician Global Assessment (PGA) | until week 24 | Assessed at baseline and at week 24. Repigmentation categories are no change, mild (1%-25%), moderate (26%-50%), good (51%-75%), and excellent (\>75%). Assessment is performed by two blinded clinicians by consensus |
| Secondary | Dermoscopic patterns and degree of repigmentation | until week 24 | |
| Secondary | Vitiligo Extent Tensity Index score | until week 24 | |
| Secondary | Patient satisfaction (A 5-point Likert scale) | 6 months after treatment. | Satisfaction-Based Scale (Direct measurement of satisfaction) * 1 - Very Dissatisfied * 2 - Dissatisfied * 3 - Neutral (or Neither Satisfied nor Dissatisfied) * 4 - Satisfied * 5 - Very Satisfied |
| Secondary | Recurrence of depigmentation | 3 months after treatment | |
| Secondary | Treatment safety/adverse events | 6 months after treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909668
GET https://conductscience.org/api/trials/v1/NCT07909668/registered